HT-0712 vs. Placebo in Subjects With Age-Associated Memory Impairment (AAMI)

• Status: Completed
• Trial end date: 2015-01-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a Phase 2 randomized, multicenter, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy of HT-0712 in improving memory and cognitive performance in subjects with Age-Associated Memory Impairment (AAMI)

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Dart NeuroScience, LLC

Criteria

Main Inclusion Criteria:

• Complaints of memory loss in everyday life

• Performance at least one standard deviation below the mean established for young adults on standardized memory tests

• Absence of dementia

• Intact global intellectual function

Main Exclusion Criteria:

• Diagnosis of Mild Cognitive Impairment (MCI) or Alzheimer's Disease

• Evidence of dementia

• Evidence of psychiatric or neurological disorder that could influence cognition or contributed to the subject's memory loss

• Use of any drugs that could influence cognition